The French journal of urology · 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC).
СтатьяКлинические рекомендацииСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roumiguié Mathieu, Leon Priscilla, Xylinas Evanguelos, Allory Yves, Audenet François, Bajeot Anne Sophie, Marcq Gautier, Prost Doriane, Thibault Constance, Masson-Lecomte Alexandra, Seisen Thomas, Pradère Benjamin, Rouprêt Morgan, Neuzillet Yann
Аннотация
OBJECTIVE: To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC).
METHODS: A systematic review (Medline) of the literature from 20222024 was performed, taking into account the elements of diagnosis, treatment options and monitoring of NMIBC and evaluating references with their level of evidence.
RESULTS: The diagnosis of NMIBC (Ta, T1, or CIS) is made after complete and deep tumour resection. The use of bladder photodynamic diagnosis and the indication for a second TURBT (4 to 6weeks later) help to improve the initial diagnosis. The risk of recurrence and/or tumour progression is assessed via the EORTC score. By stratifying patients into low-, intermediate- and high-risk groups, adjuvant treatment can be proposed, including endovesical instillations of chemotherapy (immediate postoperative regimen), BCG (induction and maintenance regimen), or even the indication of cystectomy for unresponsive patients.
CONCLUSION: Updating the CCAFU's recommendations should help improve patient management, as well as the diagnosis and treatment of NMIBC.
METHODS: A systematic review (Medline) of the literature from 20222024 was performed, taking into account the elements of diagnosis, treatment options and monitoring of NMIBC and evaluating references with their level of evidence.
RESULTS: The diagnosis of NMIBC (Ta, T1, or CIS) is made after complete and deep tumour resection. The use of bladder photodynamic diagnosis and the indication for a second TURBT (4 to 6weeks later) help to improve the initial diagnosis. The risk of recurrence and/or tumour progression is assessed via the EORTC score. By stratifying patients into low-, intermediate- and high-risk groups, adjuvant treatment can be proposed, including endovesical instillations of chemotherapy (immediate postoperative regimen), BCG (induction and maintenance regimen), or even the indication of cystectomy for unresponsive patients.
CONCLUSION: Updating the CCAFU's recommendations should help improve patient management, as well as the diagnosis and treatment of NMIBC.